{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:01:52Z","timestamp":1785211312842,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics: X"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijpx.2026.100544","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:36:46Z","timestamp":1776238606000},"page":"100544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anti-EGFR liposomal drug delivery system loaded with AGY2 potentiates the anti-cancer effect of AGY2 against EGFR expressed pancreatic cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"Raviteja","family":"Bulusu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Frimpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Okoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saunjoo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Agyare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpx.2026.100544_bb0005","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1109\/TNB.2021.3097909","article-title":"Modeling of anti-cancer drug release kinetics from liposomes and micelles: a review","volume":"20","author":"Al Sawaftah","year":"2021","journal-title":"IEEE Trans. Nanobiosci."},{"key":"10.1016\/j.ijpx.2026.100544_bb0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2026.100544_bb0015","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.3390\/biomedicines10123139","article-title":"Modeling of the in vitro release kinetics of sonosensitive targeted liposomes","volume":"10","author":"AlMajed","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijpx.2026.100544_bb0020","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.3390\/pharmaceutics14102165","article-title":"Liposomal drug delivery systems for cancer therapy: the Rotterdam experience","volume":"14","author":"Amin","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100544_bb0025","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2023","journal-title":"Genes & Diseases"},{"key":"10.1016\/j.ijpx.2026.100544_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.106007","article-title":"Implications of nanotherapeutic advancements to leverage multi-drug resistant breast cancer: the state-of-the-art review","volume":"100","author":"Aravindan","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ijpx.2026.100544_bb0035","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1007\/s00210-023-02612-4","article-title":"Ligand-based active targeting strategies for cancer theranostics","volume":"396","author":"Bandyopadhyay","year":"2023","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.ijpx.2026.100544_bb0040","doi-asserted-by":"crossref","first-page":"12222","DOI":"10.3390\/ijms241512222","article-title":"Dysregulated signalling pathways driving anticancer drug resistance","volume":"24","author":"Bou Antoun","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijpx.2026.100544_bb0045","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.62347\/ARCZ1924","article-title":"Enhanced anticancer activity of novel pyrimidine nucleoside analog in pancreatic cancer","volume":"15","author":"Bulusu","year":"2025","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ijpx.2026.100544_bb0050","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s10620-012-2036-4","article-title":"Suppression of the Epidermal Growth Factor Receptor Inhibits Epithelial\u2013Mesenchymal Transition in Human Pancreatic Cancer PANC-1 Cells","volume":"57","author":"Chang","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ijpx.2026.100544_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124109","article-title":"Enhancing breast cancer treatment: comprehensive study of gefitinib-loaded poloxamer 407\/TPGS mixed micelles through design, development, in-silico modelling, in-Vitro testing, and Ex-Vivo characterization","volume":"657","author":"Chary","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100544_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116492","article-title":"Overcoming therapy resistance in pancreatic cancer: new insights and future directions","volume":"229","author":"Espona-Fiedler","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijpx.2026.100544_bb0065","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s11095-012-0967-2","article-title":"In vitro and in vivo evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-fu: impact on efficacy and toxicity","volume":"30","author":"Fanciullino","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2026.100544_bb0070","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/08982104.2023.2268710","article-title":"Recent advances in liposome-based targeted cancer therapy","volume":"34","author":"Fidan","year":"2024","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ijpx.2026.100544_bb0075","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2174\/1389201023666220309154439","article-title":"Immunoliposomes: a targeted drug delivery system for cancer therapeutics and vaccination","volume":"24","author":"Gupta","year":"2023","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ijpx.2026.100544_bb0080","series-title":"MicroRNA Protocols","first-page":"193","article-title":"Screening miRNA for functional significance by 3D cell culture system","author":"Han","year":"2018"},{"key":"10.1016\/j.ijpx.2026.100544_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11123145","article-title":"Enhancement of chondrogenic markers by exosomes derived from cultured human synovial fluid-derived cells: a comparative analysis of 2D and 3D conditions","volume":"11","author":"Han","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijpx.2026.100544_bb0090","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0002-9440(10)65006-7","article-title":"Openings between defective endothelial cells explain tumor vessel leakiness","volume":"156","author":"Hashizume","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ijpx.2026.100544_bb0095","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer\u2014clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ijpx.2026.100544_bb0100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1517\/14712590902735795","article-title":"Mechanisms of tumor resistance to EGFR-targeted therapies","volume":"13","author":"Hopper-Borge","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ijpx.2026.100544_bb0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.chemphyslip.2016.10.005","article-title":"In vitro release kinetics model fitting of liposomes: an insight","volume":"201","author":"Jain","year":"2016","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.ijpx.2026.100544_bb0110","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/biomedicines11010217","article-title":"Green synthesized silver nanoparticle-loaded liposome-based nanoarchitectonics for cancer management: in vitro drug release analysis","volume":"11","author":"Jayachandran","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijpx.2026.100544_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.chphi.2024.100750","article-title":"Cetuximab functionalized chitosan\/hyaluronic acid-based nanoparticles loaded with cabazitaxel enhances anti-tumor efficacy in DMBA-induced breast cancer model in rats through spatial targeting","volume":"9","author":"Jha","year":"2024","journal-title":"Chem. Phys. Impact."},{"key":"10.1016\/j.ijpx.2026.100544_bb0120","doi-asserted-by":"crossref","first-page":"7789","DOI":"10.1039\/D4MA00556B","article-title":"Cabazitaxel-loaded redox-responsive nanocarrier based on d-alpha-tocopheryl-chitosan and hyaluronic acid for improved anti-tumor efficacy in DMBA-induced breast cancer model","volume":"5","author":"Jha","year":"2024","journal-title":"Mater. Adv."},{"key":"10.1016\/j.ijpx.2026.100544_bb0125","series-title":"Particle Size Analysis of Micro and Nanoparticles, Analytical Techniques in the Pharmaceutical Sciences","first-page":"677","author":"Kastner","year":"2016"},{"key":"10.1016\/j.ijpx.2026.100544_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ijpx.2026.100544_bb0135","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1080\/1061186X.2017.1408114","article-title":"Enhanced selective cellular uptake and cytotoxicity of epidermal growth factor-conjugated liposomes containing curcumin on EGFR-overexpressed pancreatic cancer cells","volume":"26","author":"Le","year":"2018","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ijpx.2026.100544_bb0140","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s13273-024-00483-1","article-title":"Review of synergistic anticancer effects of natural compounds combined with conventional therapeutics against chemoresistance and progression of pancreatic cancer","volume":"21","author":"Lee","year":"2025","journal-title":"Mol. Cell. Toxicol."},{"key":"10.1016\/j.ijpx.2026.100544_bb0145","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/17425247.2017.1247804","article-title":"The achievement of ligand-functionalized organic\/polymeric nanoparticles for treating multidrug resistant cancer","volume":"14","author":"Lee","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ijpx.2026.100544_bb0150","doi-asserted-by":"crossref","DOI":"10.5114\/aoms.2020.94845","article-title":"The global burden of pancreatic cancer","volume":"16","author":"Lippi","year":"2020","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.ijpx.2026.100544_bb0155","doi-asserted-by":"crossref","first-page":"826","DOI":"10.31128\/AJGP-06-19-4957","article-title":"Pancreatic cancer: an update on diagnosis and management","volume":"48","author":"Loveday","year":"2019","journal-title":"Aust. J. Gen. Pract."},{"key":"10.1016\/j.ijpx.2026.100544_bb0160","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jconrel.2020.05.047","article-title":"A novel kinetic model to describe the ultra-fast triggered release of thermosensitive liposomal drug delivery systems","volume":"324","author":"Lu","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2026.100544_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030915","article-title":"DOPE\/CHEMS-based EGFR-targeted immunoliposomes for docetaxel delivery: formulation development, physicochemical characterization and biological evaluation on prostate cancer cells","volume":"15","author":"Moreira","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100544_bb0170","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/ph14030221","article-title":"Lipidated peptidomimetic Ligand-Functionalized HER2 targeted liposome as Nano-carrier designed for doxorubicin delivery in cancer therapy","volume":"14","author":"Naik","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijpx.2026.100544_bb0175","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.3390\/ijms24054288","article-title":"Evaluation of anticancer activity of Zhubech, a new 5-FU analog liposomal formulation, against pancreatic cancer","volume":"24","author":"Ndemazie","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijpx.2026.100544_bb0180","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tibtech.2013.09.007","article-title":"Ligand-targeted liposome design: challenges and fundamental considerations","volume":"32","author":"Noble","year":"2014","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ijpx.2026.100544_bb0185","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/cancers3021513","article-title":"Epidermal growth factor receptor in pancreatic cancer","volume":"3","author":"Oliveira-Cunha","year":"2011","journal-title":"Cancers"},{"key":"10.1016\/j.ijpx.2026.100544_bb0190","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s11671-021-03553-8","article-title":"Liposomal nanomedicine: applications for drug delivery in cancer therapy","volume":"16","author":"Rommasi","year":"2021","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.ijpx.2026.100544_bb0195","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0005-2736(81)90385-0","article-title":"Drug-induced zeta potential changes in liposomes studied by laser Doppler spectroscopy","volume":"644","author":"Schlieper","year":"1981","journal-title":"Biochim. Et Biophys. Acta (BBA)-Biomembr."},{"key":"10.1016\/j.ijpx.2026.100544_bb0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ijpx.2026.100544_bb0205","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3390\/molecules27031086","article-title":"Stealth liposomes (PEGylated) containing an anticancer drug camptothecin: in vitro characterization and in vivo pharmacokinetic and tissue distribution study","volume":"27","author":"Sivadasan","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ijpx.2026.100544_bb0210","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3390\/pharmaceutics12100939","article-title":"Development of liposomal vesicles for osimertinib delivery to EGFR Mutation\u2014positive lung cancer cells","volume":"12","author":"Skupin-Mrugalska","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100544_bb0215","article-title":"Anti-EGFR immunoliposomes for cabazitaxel delivery: from formulation development to in vivo evaluation in prostate cancer xenograft model","volume":"661","author":"de Sousa","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100544_bb0220","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1021\/acs.chemrev.7b00013","article-title":"Ligand-targeted drug delivery","volume":"117","author":"Srinivasarao","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ijpx.2026.100544_bb0225","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejpb.2016.05.023","article-title":"Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid","volume":"105","author":"Sriraman","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2026.100544_bb0230","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1021\/acs.molpharmaceut.8b00476","article-title":"Development of high-functionality and-quality lipids with RGD peptide ligands: Application for PEGylated liposomes and analysis of intratumoral distribution in a murine colon cancer model","volume":"15","author":"Suga","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2026.100544_bb0235","first-page":"12","article-title":"Current status and future prospect of receptor targeted nanocarrier delivery of cancer therapeutics","volume":"16","author":"Yadav","year":"2025","journal-title":"J. Adv. Sci. Res."},{"key":"10.1016\/j.ijpx.2026.100544_bb0240","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1124\/pr.115.012070","article-title":"Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come","volume":"68","author":"Yingchoncharoen","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ijpx.2026.100544_bb0245","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bbcan.2009.10.001","article-title":"Targeted drug delivery in pancreatic cancer","volume":"1805","author":"Yu","year":"2010","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.ijpx.2026.100544_bb0250","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/1476-4598-13-191","article-title":"OX26\/CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma","volume":"13","author":"Yue","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ijpx.2026.100544_bb0255","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12935-022-02785-7","article-title":"Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugs","volume":"22","author":"Zhao","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ijpx.2026.100544_bb0260","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3390\/cancers17101607","article-title":"Unraveling the burden of pancreatic cancer in the 21st century: Trends in incidence, mortality, survival, and key contributing factors","volume":"17","author":"Zottl","year":"2025","journal-title":"Cancers"}],"container-title":["International Journal of Pharmaceutics: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156726000642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156726000642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:48:14Z","timestamp":1785210494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590156726000642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":52,"alternative-id":["S2590156726000642"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpx.2026.100544","relation":{},"ISSN":["2590-1567"],"issn-type":[{"value":"2590-1567","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-EGFR liposomal drug delivery system loaded with AGY2 potentiates the anti-cancer effect of AGY2 against EGFR expressed pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpx.2026.100544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100544"}}